InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.69
(
0.14%
)
Bitcoin
61,163.28
(
3.26%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

opportunityknocking

Send PM Follow Ignore
Followers 2
Posts 927
Boards Moderated 0
Alias Born 09/27/2005

opportunityknocking

Re: opportunityknocking post# 27580

Friday, 11/05/2010 5:54:51 PM

Friday, November 05, 2010 5:54:51 PM

Post# of 30387
I know one person that is not a happy camper after that press release. LOL
So you can sleep tonite: BioCurex is a leading edge biotechnology company with proprietary and patented technologies in the areas of cancer diagnosis, imaging and therapy. The Company has developed a blood test that detects 90% of all cancers based on the cancer marker, RECAF™. The RECAF test has a high sensitivity and specificity for breast and lung cancers, which are two of the most common and deadly cancers. There are no comparable cancer markers available for detection of early stages of breast and prostate cancer. BioCurex has indicated that RECAF detects cancer with higher sensitivity/specificity than
mammograms or colonoscopies.
Time to go fishing. Play nice!
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up